Could ratio of hemoglobin to red cell distribution width and ratio of absolute lymphocyte count to absolute monocyte count be a prognostic tool in newly diagnosed multiple myeloma patients?

Basit Öğe Kaydı
dc.authorscopusid56789896800
dc.authorscopusid57194148154
dc.authorscopusid57193858564
dc.authorscopusid57209211885
dc.authorscopusid26030049400
dc.authorscopusid57216286428
dc.authorscopusid57215079084
dc.contributor.authorBaysal M.
dc.contributor.authorDemirci U.
dc.contributor.authorBas V.
dc.contributor.authorGulsaran S.K.
dc.contributor.authorUmit E.
dc.contributor.authorKirkizlar H.O.
dc.contributor.authorBaysal S.
dc.date.accessioned2024-06-12T10:25:51Z
dc.date.available2024-06-12T10:25:51Z
dc.date.issued2020
dc.description.abstractHemoglobin/red cell distribution width (RDW) ratio (HRR) and lymphocyte-to-monocyte ratio (LMR) are two novel bio-markers associated with overall survival (OS) and prognosis in several types of cancers. The aim of this study is to investigate the value of HRR and LMR in newly diagnosed multiple myeloma (MM) patients. A total of 180 patients were included in this study. Patients diagnosed with MM between May 2013 and May 2019 at a single center were evaluated. HRR was calculated by dividing hemoglobin to RDW, both measured from the same sample. LMR was calculated by dividing absolute lymphocyte count (ALC) to absolute monocyte count (AMC). The cutoff value for HRR was taken as 0.61, and the cutoff value for LMR was taken as 3.28. Patients were divided into low HRR, high HRR, low LMR, and high LMR groups. OS of the patients with low HRR was found lower compared with high HRR (36.7 months for low HRR and 53.2 months for high HRR, p < 0.001). Also, OS was found lower in the low LMR group (39.4 months for low LMR and 51.7 months for high LMR, p = 0.016). On multivariate analysis, low HRR and low LMR were predictive factors of OS (hazard ratio (HR) 2.08, 95% confidence intervals (CI) 1.31-3.03, and p = 0.002 for low HRR; HR 1.47, 95% CI 0.92-2.29, and p = 0.010 for low LMR). Combining both HRR and LMR could be a prognostic biomarker and it reflects the status of the immune system in newly diagnosed MM patients. © 2020 Mehmet Baysal et al., published by Sciendo.en_US
dc.identifier.doi10.2478/ahp-2020-0016
dc.identifier.endpage87en_US
dc.identifier.issn0001-5814
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85087568232en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage81en_US
dc.identifier.urihttps://doi.org/10.2478/ahp-2020-0016
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16556
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSciendoen_US
dc.relation.ispartofActa Haematologica Polonicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemoglobin; Lymphocyte-Monocyte Ratio; Multiple Myeloma; Prognostic; Red Cell Distribution Widthen_US
dc.subjectBortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Hemoglobin; Melphalan; Prednisolone; Thalidomide; Adult; Aged; Article; Autologous Hematopoietic Stem Cell Transplantation; Cancer Diagnosis; Cancer Prognosis; Cancer Staging; Cancer Survival; Confidence Interval; Controlled Study; Female; Human; Immune System; Induction Chemotherapy; Lymphocyte Count; Lymphocyte Monocyte Ratio; Major Clinical Study; Male; Monocyte Count; Multiple Myeloma; Multivariate Analysis; Overall Survival; Red Blood Cell Distribution Width; Retrospective Studyen_US
dc.titleCould ratio of hemoglobin to red cell distribution width and ratio of absolute lymphocyte count to absolute monocyte count be a prognostic tool in newly diagnosed multiple myeloma patients?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu